Literature DB >> 6540111

Pharmacokinetics and body distribution of amiodarone in man.

T A Plomp, J M van Rossum, E O Robles de Medina, T van Lier, R A Maes.   

Abstract

The concentrations of amiodarone (Cordarone) and desethylamiodarone in plasma after single oral and intravenous and long-term oral dosing were determined in seven normal subjects and 106 patients with various cardiac arrhythmias, respectively, using a high-performance liquid chromatographic method. The decline in amiodarone plasma concentration after a single intravenous 400 mg dose was described by a triexponential decay equation, with a mean terminal half-life (t1/2) of 34.5 h. Model independent parameters were calculated from the fits. Mean values for clearance and apparent volume of distribution were 14.7 +/- 7.2 l/h and 376 +/- 372 l. Following single oral doses of 400 mg, amiodarone plasma concentration time data were fitted in a triexponential function. The mean terminal half-life for amiodarone after oral dosage was 31.6 +/- 21.3 h. Amiodarone peak concentrations of 0.37 +/- 0.22 micrograms/ml were attained in 4.8 +/- 1.5 h. The bioavailability of oral amiodarone was only 31 +/- 26%, in part due to first-pass metabolism. Desethylamiodarone , the major metabolite of amiodarone, was present in plasma in very low levels of about 10 ng/ml in several volunteers after single intravenous or oral administration of amiodarone. The mean plasma amiodarone and desethylamiodarone levels in 106 patients, using a mean oral daily maintenance dosage of 440 +/- 253 mg for a mean period of 9.1 months, were 1.85 +/- 1.17 micrograms/ml and 1.35 +/- 0.71 micrograms/ml, respectively. The relationship between the steady state amiodarone and desethylamiodarone plasma concentrations and daily amiodarone maintenance dose in mg in 106 patients was investigated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6540111

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  14 in total

1.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment.

Authors:  Matthew L Rosene; Gábor Wittmann; Rafael Arrojo e Drigo; Praful S Singru; Ronald M Lechan; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes.

Authors:  A Varró; L Virág; J G Papp
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 4.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

Review 5.  Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.

Authors:  L Bartalena; F Bogazzi; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

Review 6.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

7.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  Andrea Hofmann; Clemens Nawara; Sedat Ofluoglu; Johannes Holzmannhofer; Bernhard Strohmer; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 8.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 9.  New antiarrhythmic drugs in pediatric use: amiodarone.

Authors:  T Paul; P Guccione
Journal:  Pediatr Cardiol       Date:  1994 May-Jun       Impact factor: 1.655

10.  Amiodarone-induced myxoedema coma.

Authors:  Syed Hassan; Walaa Ayoub; Mona Hassan; Max Wisgerhof
Journal:  BMJ Case Rep       Date:  2014-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.